Relation announces two strategic collaborations with GSK

UK-based biotech Relation  today announced two multi-program strategic collaborations with pharma major GSK (LSE: GSK).

The collaborations will focus on the identification and validation of novel therapeutic targets for fibrotic diseases and osteoarthritis. These debilitating diseases affect millions of patients worldwide and represent areas of significant unmet medical need.

“These diseases have few treatments that address their root causes,” said David Roblin, chief executive of Relation, adding: “By combining Relation’s patient-centric discovery platform with GSK’s global scale and expertise, we have the potential to accelerate the development of transformative medicines for patients who have long awaited new therapies.”